PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34486176-4	2021	Lixivaptan is expected to have a safer liver profile compared to tolvaptan, the only drug approved to delay PKD progression, based on computational model results and initial clinical evidence.	Tolvaptan	65-74	protein kinase D1	Homo sapiens	108-111	
28194574-5	2017	CONCLUSION: Tolvaptan may be a useful treatment for severe neonatal PKD.	Tolvaptan	12-21	protein kinase D1	Homo sapiens	68-71